Alterity Therapeutics (ATHE) Liabilities and Shareholders Equity (2009 - 2025)

Alterity Therapeutics' Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $37.4 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 441.83% year-over-year to $37.4 million; the TTM figure through Dec 2025 stood at $86.4 million (up 65.32% YoY), while the FY2025 annual figure was $29.5 million, up 132.67% from the prior year.
• Liabilities and Shareholders Equity was $37.4 million for Q4 2025 at Alterity Therapeutics, up from $29.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $37.4 million in Q4 2025 to a low of $6.9 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $22.9 million across 5 years, with a median of $23.9 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity plunged 52.26% in 2024, then jumped 441.83% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $32.7 million in 2021, then tumbled by 32.99% to $21.9 million in 2022, then sank by 34.13% to $14.4 million in 2023, then slumped by 52.26% to $6.9 million in 2024, then surged by 441.83% to $37.4 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $37.4 million (Q4 2025), $29.5 million (Q2 2025), and $6.9 million (Q4 2024), per Business Quant data.